Li Wenke, Wei Jing, Cheng Mo, Liu Ming
Gastric Cancer Center/Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province 610041, China.
Mol Ther Oncol. 2024 Aug 5;32(3):200857. doi: 10.1016/j.omton.2024.200857. eCollection 2024 Sep 19.
Gastric cancer (GC) poses a significant global health challenge, ranking fifth in incidence and third in mortality among all malignancies worldwide. Its insidious onset, aggressive growth, proclivity for metastasis, and limited treatment options have contributed to its high fatality rate. Traditional approaches for GC treatment primarily involve surgery and chemotherapy. However, there is growing interest in targeted therapies and immunotherapies. This comprehensive review highlights recent advancements in GC targeted therapy and immunotherapy. It delves into the mechanisms of various strategies, underscoring their potential in GC treatment. Additionally, the review evaluates the efficacy and safety of relevant clinical trials. Despite the benefits observed in numerous advanced GC patients with targeted therapies and immunotherapies, challenges persist. We discuss pertinent strategies to overcome these challenges, thereby providing a solid foundation for enhancing the clinical effectiveness of targeted therapies and immunotherapies.
胃癌(GC)对全球健康构成重大挑战,在全球所有恶性肿瘤中,其发病率排名第五,死亡率排名第三。其发病隐匿、生长侵袭性强、易于转移且治疗选择有限,这些因素导致了其高死亡率。传统的胃癌治疗方法主要包括手术和化疗。然而,靶向治疗和免疫治疗越来越受到关注。这篇综述重点介绍了胃癌靶向治疗和免疫治疗的最新进展。它深入探讨了各种策略的作用机制,强调了它们在胃癌治疗中的潜力。此外,该综述还评估了相关临床试验的疗效和安全性。尽管在许多晚期胃癌患者中,靶向治疗和免疫治疗取得了一定疗效,但挑战依然存在。我们讨论了克服这些挑战的相关策略,从而为提高靶向治疗和免疫治疗的临床效果奠定坚实基础。